FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCity Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CTY
City Therapeutics Inc. Stock AnalysisComprehensive stock analysis for City Therapeutics Inc. (CTY) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCTY
CTY
City Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CTY
  1. Home
  2. Stocks
  3. City Therapeutics Inc.
CT

City Therapeutics Inc.

🇺🇸CTY•NASDAQ
CT

City Therapeutics Inc.

🇺🇸CTY•NASDAQ
Market cap
$888.37M
Sentiment

Your view on CTY

Mkt Cap
$888.37M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About City Therapeutics Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Andrew C. Orth
Headquarters
399 Binney Street, Cambridge, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Andrew C. Orth
Headquarters
399 Binney Street, Cambridge, MA, US
Description

City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA.

The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets.

Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease.

The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for City Therapeutics Inc. from FRC's valuation model, read against the market price. CTY last traded at $16.64; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for City Therapeutics Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for City Therapeutics Inc.. City Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for City Therapeutics Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for City Therapeutics Inc.. City Therapeutics Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CTY12 companies · 6 funds

More Biotechnology companies

Market cap

  • AVTXAvalo Therapeutics, Inc.NASDAQ$387M
  • AVXLAnavex Life Sciences Corp.NASDAQ$67M
  • AXIMAXIM Biotechnologies, Inc.OTC$4M
  • AXSMAxsome Therapeutics, Inc.NASDAQ$7.0B
  • AZTRAzitra, Inc.AMEX$3M
  • BBIOBridgeBio Pharma, Inc.NASDAQ$15.2B
  • BBIXFBonus BioGroup Ltd.OTC$158M
  • BBLGBone Biologics CorporationNASDAQ$986,216
  • BBLGWBone Biologics CorporationNASDAQ$1M
  • BBOTBridgeBio Oncology Therapeutics Inc.NASDAQ$145M
  • BBTXBambusa Therapeutics Inc.NASDAQ$810M
  • BCABBioAtla, Inc.NASDAQ$3M

ETFs holding City Therapeutics Inc.

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • HRTSTema Cardiovascular and Metabolic ETF$58M in assets0.32%
  • VTWOVanguard Russell 2000 ETF$16.6B in assets0.00%
  • VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.00%
  • VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.00%

Largest holders first, then the funds most concentrated in CTY.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold City Therapeutics Inc., and how their positions are changing. At a $888.4M market value, institutional positions materially move City Therapeutics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by City Therapeutics Inc. executives and directors. Shares of City Therapeutics Inc. have traded between $15.81 and $23.88 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming City Therapeutics Inc.. City Therapeutics Inc. is a $888.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming City Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for City Therapeutics Inc.. Coverage tracks City Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of City Therapeutics Inc.

CTY Analysis
Fair
Past1
Growth2
Health3
Profit3
Value5

News

Latest Market News